Biopharmaceutical News and Research

RSS

Stealth presents Bendavia at AHA's Cardiovascular Scientific Sessions

Stealth Peptides Inc. (Stealth), a privately held biopharmaceutical company developing innovative mitochondrial therapies for diseases with unmet medical needs, presented its lead clinical candidate, Bendavia, during the 2011 American Heart Association's (AHA) Cardiovascular Scientific Sessions.

1 Aug 2011

New protein discovery could help develop intracellular biologic drugs

Permeon Biologics, a biopharmaceutical company pioneering a novel class of intracellular protein biologics, today announced the discovery of an entirely new class of naturally occurring human supercharged proteins called Intraphilins-.

29 Jul 2011

Sigma-Tau, Soligenix expand partnership to develop and commercialize orBec in Europe

Soligenix, Inc., a late-stage biopharmaceutical company, announces the expansion and amendment of its North American licensing partnership with Sigma-Tau Pharmaceuticals, Inc. for the development and commercialization of orBec into the European territory.

29 Jul 2011

CytRx prices underwritten public offering of common stock

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that it has priced an underwritten public offering of 39,200,000 shares of common stock and warrants to purchase up to 39,200,000 shares of common stock at a combined public offering price of $0.52 per share and related warrant for gross proceeds of approximately $20.4 million.

27 Jul 2011

Repligen first quarter total revenue increases 9% to $7,654,000

Repligen Corporation today reported results for the first quarter of fiscal year 2012, ended June 30, 2011.

27 Jul 2011

New preclinical data suggests microRNA-15 inhibits cardiomyogenesis

miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients' lives by developing innovative microRNA (miRNA)-based therapeutics for cardiovascular and muscle disease, announced today that new preclinical data published in the online edition of Circulation Research suggests that microRNA-15 (miR-15) inhibits cardiomyogenesis, the process whereby new heart muscle cells are formed.

27 Jul 2011

Viewpoints: The effects of the debt debate; Medicare's birthday; N.Y. drug plan

In the scramble to cut the nation's debt burden, President Obama, congressional Democrats and even some Republicans have proposed squeezing money out of Medicare by changing the way it pays for prescription drugs.

27 Jul 2011

NeurOp receives NIH grant to support research program for ischemia

NeurOp, Inc., a biopharmaceutical company developing new treatments for central nervous system disorders, today announced that the National Institutes of Health (NIH) has awarded the company a $3 million grant to support its research program for ischemia.

27 Jul 2011

BioWa, arGEN-X sign license agreement for POTELLIGENT Technology

arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies from its proprietary SIMPLE Antibody platform, announces it has signed a non-exclusive license agreement with BioWa Inc., the exclusive worldwide licensor of POTELLIGENT Technology.

26 Jul 2011

Debiopharm, INC Research partner for clinical development programmes

INC Research, LLC, a therapeutically focused contract research organisation (CRO) with a trusted process for delivering reliable results, and Debiopharm Group, a Swiss-based global biopharmaceutical group with a focus on drug development and companion diagnostics, today announced a strategic partnership.

26 Jul 2011

Decision Resources announces acquisition of PharmaStrat

Decision Resources Group, one of the world's leading research and advisory firms focusing on healthcare insights and analysis, announced today that it acquired PharmaStrat, the leading consulting and market research services firm focused on issues related to reimbursement and organized customer segments for biopharmaceutical manufacturers.

26 Jul 2011

Mayo Clinic trial to evaluate folate receptor alpha-targeted breast/ovarian cancer vaccine

VaxOnco, a leading oncology biopharmaceutical company, today announced that following FDA IND approval, it will sponsor a Phase I folate receptor alpha-targeted therapeutic vaccine clinical trial in disease-free patients, previously diagnosed with either breast or ovarian cancer at Mayo Clinic.

25 Jul 2011

Galectin, University of Michigan enter collaboration to study role of Galectins in cardiovascular disease

Galectin Therapeutics Inc. today announced that it has entered into a research collaboration with Dr. Jose Jalife of the University of Michigan Medical School to better understand the relationship of Galectin-3 to cardiac fibrosis in chronic cardiac arrhythmias.

21 Jul 2011

Identification of third microRNA target triggers milestone payment from GSK to Regulus

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it has identified a third microRNA target in its alliance with GlaxoSmithKline (GSK), triggering a preclinical milestone payment from GSK.

21 Jul 2011

PAREXEL completes 100th Asian ethnobridging study

PAREXEL International Corporation, a leading global biopharmaceutical services provider, announced today that it has achieved a significant milestone by completing its 100th Asian ethnobridging study, which is designed to help biopharmaceutical companies accelerate development for the Asia/Pacific market.

From Parexel 21 Jul 2011

Malvern and Paraytec enter into development and technology licensing agreement

Malvern Panalytical (Malvern Panalytical, UK) and Paraytec Ltd (York, UK) have entered into a development and licensing agreement that will see Paraytec’s ActiPix® technology being added to Malvern Panalytical’s materials characterization portfolio. The agreement will give Malvern Panalytical exclusive rights to further develop, market and sell ActiPix® UV area imaging technology in specific fields of use related to the characterization of complex fluids for applications in biopharmaceuticals, foods and personal care industrial sectors.

From Malvern Panalytical 20 Jul 2011

Two existing clinical stage clients expand development activities with Progenitor Cell Therapy

Progenitor Cell Therapy (PCT), an internationally recognized cell therapy services and development company, and a wholly-owned subsidiary of NeoStem, Inc., an international biopharmaceutical company with operations in the U.S. and China, announced today that two existing clinical stage biopharmaceutical corporate clients have chosen to expand their development activities with PCT.

18 Jul 2011

WebMD anticipates 15% increase in revenue for second quarter 2011

WebMD Health Corp., the leading source of health information, today announced preliminary financial results for the three months ended June 30, 2011 and updated financial guidance for 2011.

18 Jul 2011

FDA approves Shire's Lialda for maintenance of remission of ulcerative colitis

Shire plc, the global specialty biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) approved Lialda® (mesalamine) Delayed Release Tablets for the maintenance of remission in patients with ulcerative colitis.

18 Jul 2011

Sofinnova Ventures leads $44 million Series B private equity financing for SARcode Bioscience

SARcode Bioscience, Inc., a privately-held biopharmaceutical company, announced today the completion of a $44 million Series B private equity financing. The financing round was led by Sofinnova Ventures and was augmented by the additional backing of Rho Ventures and existing investors Alta Partners and Clarus Venture Partners.

18 Jul 2011